GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PetIQ Inc (NAS:PETQ) » Definitions » Research & Development

PetIQ (PETQ) Research & Development : $0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is PetIQ Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. PetIQ's Research & Development for the three months ended in Mar. 2024 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was $0 Mil.

PetIQ Research & Development Historical Data

The historical data trend for PetIQ's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetIQ Research & Development Chart

PetIQ Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only - - - - -

PetIQ Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

PetIQ Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PetIQ  (NAS:PETQ) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

PetIQ Research & Development Related Terms

Thank you for viewing the detailed overview of PetIQ's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

PetIQ (PETQ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PetIQ Inc (NAS:PETQ) » Definitions » Research & Development
Comparable Companies
HROW AMRX PAHC EOLS SIGA PROC COLL BKUH ORGO LFCR ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
39L:Germany
Address
230 East Riverside Drive, Eagle, ID, USA, 83616
Website
https://www.petiq.com
PetIQ Inc is a manufacturer and distributor of health and wellness products for dogs and cats. The company offers veterinarian-grade pet Rx medications, OTC flea and tick preventatives, vitamins treats, nutritional supplements, and hygiene products. The group operates in two segments namely the Products and Services segments. It also provides third-party products to retailers which for a long time were primarily available from veterinary clinics only. Its proprietary brands include PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, TruProfen, Betsy Farms, PetAction, Minties, Vera and Delightibles. The company generates maximum revenue from Products segment.
Executives
William J. Carter officer: EVP, GENERAL COUNSEL C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
John Paul Pearson officer: EVP, Services & Manufactured C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Robert Michael Herrman officer: General Counsel and Secretary 923 SOUTH BRIDGEWAY PLACE, EAGLE ID 83616
Michael A Smith officer: EVP - Products 923 S. BRIDGEWAY PLACE, C/O PETIQ, INC., EAGLE ID 83616
Kimberly Lefko director 923 S. BRIDGEWAY PLACE, EAGLE ID 83616
Sheryl Oloughlin director 923 S. BRIDGEWAY PLACE, EAGLE ID 83616
Scott Huff director 923. S. BRIDGEWAY PLACE, EAGLE ID 83616
Allan Hall director C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Zvi Glasman officer: Chief Financial Officer C/O FOX FACTORY HOLDING CORP., 915 DISC DRIVE, SCOTTS VALLEY CA 95066
Kenneth C. Walker director C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Susan Sholtis director C/O PETIQ, INC., 500 E. SHORE DRIVE, SUITE 120, EAGLE ID 83616
Mccord Christensen director, officer: Chief Executive Officer 500 EAST SHORE DRIVE, SUITE 120, EAGLE ID 83616
John Newland officer: Chief Financial Officer C/O TRUE SCIENCE LLC, 500 E. SHORE DRIVE SUITE 120, EAGLE ID 83616
Ronald Kennedy director, 10 percent owner 500 EAST SHORE DR, SUITE 120, EAGLE ID 83616
Ecp Helios Partners Iv, L.p. 10 percent owner 437 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022